FDA approves Allergan's migraine tablet ahead of AbbVie merg...

Allergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with or without aura.

Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up

Two biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for epilepsy in a deal worth up to $1.75 billion.

Alkermes bolts on Rodin Therapeutics to bulk up thin pipelin...

Merck builds in CNS diseases with $576m Calporta buy

Biogen bags FDA okay for Tecfidera follow-up Vumerity

Searching for new hope in Alzheimer’s

For the best part of two decades, it seemed as if pharma hit a brick wall as it tried to find new treatments for Alzheimer’s.